12/6/2023 0 Comments Eclipse development llc address(Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360 ® CDx as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader (SERD ) being studied in the treatment of advanced ER-positive, HER2-negative breast cancer resistant to CDK4/6 inhibitors in combination with hormone therapy. REDWOOD CITY, Calif., J(GLOBE NEWSWIRE) - Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast Cancer
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |